^
Association details:
Evidence:
Evidence Level:
Resistant: A2 - Guideline
New
Source:
Excerpt:
Colorectal cancer...the panel recommends against the use of mitomycin, alfa-interferon, taxanes, methotrexate, pemetrexed, sunitinib, sorafenib, erlotinib, or gemcitabine, either as single agents or in combination, as therapy in patients exhibiting disease progression after treatment with standard therapies.